Centre bans fixed-dose combination for Common Cold in children below four

The ministry said the use of “Chlorpheniramine Maleate and Phenylephrine Hydrochloride” drug combination in children below four years could pose health risks, while their safer alternatives are available in the market.

New Delhi: The Central government has prohibited the sale and use of the fixed-dose combination (FDC) of “Chlorpheniramine Maleate and Phenylephrine Hydrochloride in children below four years of age”, citing potential health risks.

In a gazette notification, the Union Health Ministry directed manufacturers of the concerned FDCs to carry a warning stating, “The drug shall not be used in children below four years of age.”

The ministry said the use of these medicines in children below four years could pose health risks, while their safer alternatives are available in the market.

Phenylephrine hydrochloride and chlorpheniramine maleate combination is used to treat symptoms of the common cold, flu, and allergies, such as a stuffy nose, sneezing, and watery eyes.

However, an expert committee constituted by the Ministry examined the matter, reviewed the FDC and flagged potential health risks for children. It recommended that a warning label be placed on all drugs containing the two salts that are manufactured and sold across the country.

Later, the Drugs Technical Advisory Board (DTAB) also endorsed the proposal at its meeting held on February 16, 2026.

Notably, the latest move comes in a series of crackdowns over the past 12 months, during which the ministry has imposed a complete ban or restricted sale of more than 50 irrational combinations. Most recently, 16 FDCs were banned in June this year.

According to multiple reports, the central regulator –CDSCO– is undertaking a review of legacy products and older FDCs, particularly those with incomplete or outdated records, to strengthen regulatory oversight and enforce quality and safety norms.

Meanwhile, the scrutiny of common-cold therapies has intensified following the deaths of at least 24 children in Madhya Pradesh last year and several state agencies have also imposed similar restrictions on use of such drug combinations in children.

  • Related Posts

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

    Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, announced the expansion of its BubbleGen cell selection portfolio with the launch of the BubbleGen CD3+…

    5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

    Jaipur: Rajasthan Food Safety and Drug Control Commissionerate has launched a manufacturer-level investigation after five medicine samples seized during a raid on an unlicensed drug warehouse in Bhiwadi on Sept…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

    5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

    5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

    AiMeD welcomes govt’s offer supporting development of advanced testing infrastructure

    AiMeD welcomes govt’s offer supporting development of advanced testing infrastructure

    Eluru police arrest five medical shop owners for illegal sale of Tramadol injections

    Eluru police arrest five medical shop owners for illegal sale of Tramadol injections

    KAISHA Pharma establishes Kaisha Pharma International in Italy

    KAISHA Pharma establishes Kaisha Pharma International in Italy

    Apollo Navi Mumbai launches geriatric oncology clinic

    Apollo Navi Mumbai launches geriatric oncology clinic